Nivolumab in renal transplant recipients with poor prognosis cancers - a safety study.

Trial Profile

Nivolumab in renal transplant recipients with poor prognosis cancers - a safety study.

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 24 May 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Breast cancer; Colorectal cancer; Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 24 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top